Chinese english Germany Japanese Korea

D-erythro-Pent-4-enose, 4,5-dideoxy-2,3-O-(1-methylethylidene)- (9CI)

D-erythro-Pent-4-enose, 4,5-dideoxy-2,3-O-(1-methylethylidene)- (9CI) Struktur
155934-55-7
CAS-Nr.
155934-55-7
Englisch Name:
D-erythro-Pent-4-enose, 4,5-dideoxy-2,3-O-(1-methylethylidene)- (9CI)
Synonyma:
Ticagrelor Impurity 128;(4R,5R)-2,2-dimethyl-5-vinyl-[1,3]dioxolane-4-carbaldehyde;D-erythro-Pent-4-enose, 4,5-dideoxy-2,3-O-(1-methylethylidene)-;D-erythro-Pent-4-enose, 4,5-dideoxy-2,3-O-(1-methylethylidene)- (9CI)
CBNumber:
CB51065351
Summenformel:
C8H12O3
Molgewicht:
156.18
MOL-Datei:
155934-55-7.mol
Request For Quotation

D-erythro-Pent-4-enose, 4,5-dideoxy-2,3-O-(1-methylethylidene)- (9CI) Eigenschaften

Siedepunkt:
212.8±40.0 °C(Predicted)
Dichte
1.142±0.06 g/cm3(Predicted)

Sicherheit

D-erythro-Pent-4-enose, 4,5-dideoxy-2,3-O-(1-methylethylidene)- (9CI) Chemische Eigenschaften,Einsatz,Produktion Methoden

D-erythro-Pent-4-enose, 4,5-dideoxy-2,3-O-(1-methylethylidene)- (9CI) Upstream-Materialien And Downstream Produkte

Upstream-Materialien

Downstream Produkte

(3aR,4S,6R,6aS)-6-Aminotetrahydro-2,2-dimethyl-4H-cyclopenta-1,3-dioxol-4-ol 4,7-Methano-4H-1,3-dioxolo[4,5-d][1,2]oxazine, tetrahydro-2,2-dimethyl-6-(phenylmethyl)-, (3aS,4S,7R,7aS)-

D-erythro-Pent-4-enose, 4,5-dideoxy-2,3-O-(1-methylethylidene)- (9CI) Anbieter Lieferant Produzent Hersteller Vertrieb Händler.

Global( 4)Lieferanten
Firmenname Telefon E-Mail Land Produktkatalog Edge Rate
Molcoo Chemicals Inc. 18627923403 18627753421
 3001006472@qq.com China 9161 58
Beijing Qinling Pharmaceutical Co., Ltd. 010-61241352 18901327973
 sales@qlmed.com China 4041 58
Hubei Moco Chemical Co., Ltd. 18627753421 17386083646
 3001009495@qq.com China 10901 58
  • D-erythro-Pent-4-enose, 4,5-dideoxy-2,3-O-(1-methylethylidene)- (9CI)
  • D-erythro-Pent-4-enose, 4,5-dideoxy-2,3-O-(1-methylethylidene)-
  • Ticagrelor Impurity 128
  • (4R,5R)-2,2-dimethyl-5-vinyl-[1,3]dioxolane-4-carbaldehyde
  • 155934-55-7
  • ALDEHYDE
Copyright 2019 © ChemicalBook. All rights reserved